[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cin-23\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cin-23":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,90,119,145,176],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100640087","peripheral-blood-cytof-immune-model-for-cervical-lesion-detection-in-hpv1618-women-100640087",false,"NCT07606677","Peripheral Blood CyTOF Immune Model for Cervical Lesion Detection in HPV16\u002F18+ Women","Mass Cytometry-based Peripheral Blood Immune Model for Accurate Detection of Cervical Lesions in HPV16\u002F18-positive Women: a Multicenter Study","Inclusion Criteria:\n\n* Availability of cervical cytology results\n* Consent to colposcopy and cervical biopsy\n* Signed informed consent\n\nExclusion Criteria:\n\n* Confirmed diagnosis of CIN2 or worse\n* Prior cervical ablation, cervical conization, chemoradiotherapy, or immunotherapy\n* Other malignancy within the past 2 years not in complete remission\n* Presence of other systemic immune disease or active infection\n* Pregnancy or lactation\n* Inability to comply with follow-up and examinations\n* Inability to comply with study procedures, restrictions, and requirements, as determined by the investigator","FEMALE","25 Years","65 Years",{"count":20,"type":21},1465,"ESTIMATED","OBSERVATIONAL","This prospective, multicenter cohort study will recruit eligible HPV16\u002F18-positive women from three tertiary hospitals in China. Peripheral blood samples and clinical data (cytology, HPV genotyping, colposcopy-directed biopsy) will be collected, followed by standardized mass cytometry (CyTOF) to develop and evaluate an immune model across cervical lesion grades.",[25,26],"CIN 2\u002F3","Cervical Cancer (Early Detection)",[28,29,30,31,32],"cervical cancer","Cervical Intraepithelial Neoplasia","HPV16\u002F18","Mass cytometry","Immune model","NOT_YET_RECRUITING","2026-05-18",{"date":36,"type":37},"2026-05-26","ACTUAL",{"date":39,"type":21},"2026-05-15",{"date":41,"type":21},"2028-03-31",{"name":43,"class":44},"Women's Hospital School Of Medicine Zhejiang University","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100370084","phase-2-artesunate-vaginal-inserts-for-the-treatment-of-cervical-intraepithelial-neoplasia-cin23-100370084","NCT04098744","Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2\u002F3)","A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2\u002F3)","ART-CIN_IIB","Inclusion Criteria:\n\n* Adult females age ≥ 25 years\n* Capable of informed consent\n* Any HPV genotype detectable by DNA test\u002FHPV genotyping\n* Colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2\u002F3)\n* Women of childbearing potential agree to use birth control through week17 of the study.\n* Weight ≥ 50kg\n\nExclusion Criteria:\n\n* Pregnant and nursing women\n* Active autoimmune disease\n* Taking immunosuppressive medication\n* HIV seropositivity\n* Immunocompromised subjects\n* Evidence of concurrent cervical adenocarcinoma in situ\n* Concurrent malignancy except for nonmelanoma skin lesions, because treatment for other cancers have systemic effects","100 Years",{"count":55,"type":21},78,"INTERVENTIONAL",[58],"PHASE2","This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2\u002F3).",[25,61,62,63,64],"HPV Infection","Pre-Cancerous Dysplasia","Cervical Dysplasia","HPV Related Disease",[66,67,68,69,70,71,72,73,74,75,76,77],"treatment study","cancer prevention","non-surgical","HPV related disease","CIN","topical treatment","vaginal inserts","artesunate","artemisinin","non-invasive","high risk HPV","vaginal suppository","RECRUITING","2025-09-29",{"date":81,"type":37},"2025-10-02",{"date":83,"type":37},"2020-09-09",{"date":85,"type":21},"2026-12-31",{"name":87,"class":88},"Frantz Viral Therapeutics, LLC","INDUSTRY",7,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":56,"phases":101,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100600283","phase-2-safety-and-efficacy-of-oral-artesunate-for-pre-cervical-cancer-100600283","NCT07095478","Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer","Phase II Single Arm, Open Label Study of Artesunate for the Treatment of Human Papilloma Virus Positive High Grade Cervical Intraepithelial Neoplasia (CIN2\u002F3)","NeoART-CIN","Inclusion Criteria:\n\n* Aged 18 or over\n* Histologically proven HPV positive cervical CIN2\u002F3\n* WHO performance status 0-2\n* Adequate full blood count:\n* White Cell Count (WCC) \\>3.0 x 109 \u002Fl;\n* Platelets \\>100 x 109\u002Fl;\n* Haemoglobin (Hb) \\>80g\u002FL\n* Adequate renal function:\n* Glomerular Filtration Rate \\>30ml\u002Fmin\n* Adequate hepatobiliary function:\n* Total bilirubin \\\u003C 3 x Upper limit normal\n* Female participants of child bearing potential must have a negative pregnancy test \\\u003C 72 hours prior to initiating study intervention and agree to avoid pregnancy using adequate, medically approved contraceptive precautions for up to 6 weeks after the last dose of study treatment intervention\n* Patient able and willing to provide written, informed consent for the study\n\nExclusion Criteria:\n\n* • Contraindication to the use of artesunate due to hypersensitivity\n\n  * Pregnancy or lactation\n  * Weight \\\u003C 52 kg\n  * History of previous CIN\n  * Immunocompromised patients","18 Years",{"count":100,"type":21},28,[58],"NeoART-CIN is a Phase II clinical study evaluating the safety and effectiveness of oral artesunate in patients with pre-cancerous cervical intra-epithelial neoplasia (CIN2\u002F3), to investigate if a course of treatment with oral artesunate can reverse pre-cancerous changes in the cervix and prevent the development and progression of invasive cancer. Findings from this study will increase our understanding of the effects of artesunate on CIN2\u002F3 and if confirmatory inform future clinical studies.",[25],[70,105,106,107,108],"HPV","drug repurposing","Artesunate","antimalarial","2025-07-23",{"date":111,"type":37},"2025-07-31",{"date":113,"type":21},"2025-08-01",{"date":115,"type":21},"2028-06-30",{"name":117,"class":88},"Metanoic Health Ltd.",5,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":56,"phases":129,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":144},"100541164","assessment-of-the-effectiveness-of-ta-versus-leep-for-cervical-cancer-risk-reduction-in-wlhiv-in-mozambique-100541164","NCT06326294","Assessment of the Effectiveness of TA Versus LEEP for Cervical Cancer Risk Reduction in WLHIV in Mozambique","A Randomized Clinical Trial to Assess the Effectiveness of Thermal Ablation Versus Loop Electrosurgical Excision Procedure for Cervical Cancer Risk Reduction in Women Living With Human Immunodeficiency Virus in Mozambique","Inclusion Criteria:\n\n* ages 25-49 years;\n* confirmed HIV infection;\n* physically and mentally willing and able to participate in the study, and provide informed consent.\n\nExclusion Criteria:\n\n* currently pregnant or \\\u003C6 weeks post-partum;\n* had a hysterectomy and no longer have a cervix;\n* a history of cervical cancer or treatment for cervical abnormalities; and\n* any medical, psychiatric, or other condition that would interfere with protocol adherence, assessment of safety, and\u002For ability\u002Fcompetence to provide informed consent.","49 Years",{"count":128,"type":21},4844,[130],"NA","Given that WLWH are more likely to develop persistent HPV infection and CC, effective screening and the management and treatment of pre-cancerous cervical abnormalities is critical to decrease the global burden of cervical cancer. The vast majority of WLWH live in SSA, where resources are more constrained. Therefore, simple, affordable, and effective tools are needed for the prevention of cervical cancer in SSA. In this setting, the best method for treatment of screen-positive WLWH has not been determined. The proposed study will compare the effectiveness of TA vs. LEEP, for treating precursor lesions (CIN 2\u002F3) and HPV infection in WLWH, identify the determinants of treatment failure, and develop a strategy to predict patients in whom treatment is likely to fail so that alternative treatments can be provided. Moreover, local evidence of the optimal method of treatments is necessary to inform health policy and promote adherence.",[133,61,25],"HIV Infections","2024-05-21",{"date":136,"type":37},"2024-05-22",{"date":138,"type":37},"2024-04-17",{"date":140,"type":21},"2027-12",{"name":142,"class":143},"Instituto Nacional de Saúde, Mozambique","OTHER_GOV",1,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":4,"enrollmentInfo":152,"targetDuration":154,"studyType":22,"phases":4,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":175},"100470393","predicting-response-in-cervical-intraepithelial-neoplasia-to-topical-imiquimod-treatment-100470393","NCT05405270","Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment","PRedICT-TOPIC","Inclusion Criteria:\n\n* Primary cHSIL lesions (e.g. CIN3 or CIN 2), histologically confirmed by diagnostic biopsy Nota bene: In case of CIN 2, expectative management must be discussed according to the Dutch national guideline with the patient, if the patient prefers imiquimod therapy the patient can be treated with imiquimod and enrolled in the study, if the patient prefers expectative management they can be enrolled in the observational CIN 2 group.\n* Recurrent or residual cHSIL lesions after initial LLETZ treatment (e.g. CIN2 or CIN3), histologically confirmed by diagnostic biopsy\n* Age of 18 years or older\n\nExclusion Criteria:\n\n* Concomitant diagnoses of VAIN (vaginal intraepithelial neoplasia e.g. vaginal HSIL)\n* PAP (Papanicolaou) 4 cytology as indication for the baseline colposcopy at study entrance\n* Adenocarcinoma in situ (AIS) diagnosis\n* Previous imiquimod therapy for cHSIL\n* Previous cervical malignancy\n* Current malignant disease\n* Immunodeficiency (including HIV\u002FAIDS and immunosuppressive medication)\n* Pregnancy\n* Legal incapability\n* Insufficient knowledge of the Dutch language",{"count":153,"type":21},410,"2 Years","Imiquimod is a good non-invasive treatment option for women with cervical high-grade squamous intraepithelial neoplasia (cHSIL), especially those with a possible (future) pregnancy wish. Complete response to imiquimod occurs in 55-73% of patients, however side-effects of imiquimod are common and can be extensive. Therefore, biomarkers which can predict response to imiquimod therapy are warranted, to increase therapy efficacy and to avoid side effects in patients who will not respond.\n\nThis prospective, multi-center cohort study aims to validate the potential of immune related biomarkers to predict the clinical response of patients with primary cHSIL to imiquimod, aims to explore the value of these immune biomarkers in recurrent\u002Fresidual cHSIL to predict treatment responses for imiquimod and aims to explore their potential in spontaneous regression of cHSIL (CIN2).",[157,158,25,29],"Cervical High Grade Squamous Intraepithelial Lesion","Cervical Intraepithelial Neoplasia Grade 2\u002F3",[160,161,162,163,164,165],"Cervical high-grade squamous intraepithelial lesion (cHSIL)","Imiquimod","Tumor immunemicroenvironment","High-risk human papilloma virus (hrHPV)","Cervical intraepithelial neoplasia (CIN)","Biomarker","2023-09-08",{"date":168,"type":37},"2023-09-11",{"date":170,"type":37},"2022-06-01",{"date":172,"type":21},"2026-12",{"name":174,"class":44},"Catharina Ziekenhuis Eindhoven",15,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":183,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":56,"phases":187,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":144},"100432414","phase-4-concomitant-hpv-vaccination-and-hpv-screening-hpv-infection-and-cervical-cancer-in-sweden-100432414","NCT04910802","Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden","Concomitant HPV Vaccination and HPV Screening for Rapid Elimination of HPV Infection and Cervical Cancer in Sweden","Inclusion Criteria:\n\n* Eligible women will include resident women within the age range of 22-26, who have not opted out of the screening program and who consent to participate in the study.\n\nWomen who respond to the invitation and attend screening will be screened with HPV testing by the current routine practise. Women who consent to participate will also be offered HPV vaccination. The HPV vaccine (Gardasil 9) will be offered regardless of whether the woman reports having had prior vaccination with a first-generation vaccine (Gardasil 4) and regardless of screening test result.\n\nExclusion Criteria:\n\n1. Known history of severe allergic reaction or hypersensitivity to any of the components of the HPV vaccine.For GARDASIL 9: Amorphous aluminium hydroxyphosphate sulphate adjuvant, Sodium chloride, L-histidine, Polysorbate 80 or Sodium borate\n2. Known history of immune-related disorders\n3. Current acute severe febrile illness, except for minor infections such as a cold, mild upper respiratory infection or low-grade fever.\n4. Administration of immunoglobulin or blood-derived products within 6 months prior to scheduled HPV vaccine first dose\n5. Current pregnancy (reported)\n6. Women with a total hysterectomy","22 Years","27 Years",{"count":186,"type":21},150000,[188],"PHASE4","The study aims to evaluate whether organised, concomitant HPV vaccination and HPV screening offered to all resident women aged 22-27 will result in a more rapid elimination of HPV infection in Sweden. This objective will be examined at the population level.",[61,25,191],"Cervical Cancer","2021-09-09",{"date":194,"type":37},"2021-09-16",{"date":196,"type":37},"2021-05-03",{"date":198,"type":21},"2027-12-31",{"name":200,"class":143},"Miriam Elfström"]